|
GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis
|
17 November 2022 |
|
GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D
|
18 October 2022 |
|
WHO grants prequalification to GSK's Mosquirix - the first and only approved malaria vaccine
|
19 September 2022 |
|
GSK signs agreement to support pandemic preparedness in Europe
|
01 August 2022 |
|
GSK completes acquisition of Sierra Oncology
|
04 July 2022 |
|
GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries
|
23 June 2022 |
|
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
|
02 June 2022 |
|
SK bioscience and GSK's adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study
|
29 April 2022 |
|
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
|
14 April 2022 |
|
GSK announces independent Consumer Healthcare company is to be called Haleon
|
22 February 2022 |